F S&P 500
5,071.50 +25.00 (+0.50%) F Dow Jones
38,217.00 +148.00 (+0.39%) F Nasdaq
17,547.50 +109.25 (+0.63%) E-mini Russell 2000 Index Futur
2,005.70 +16.00 (+0.80%) Petróleo
79.52 +0.52 (+0.66%) Oro
2,329.20 +18.20 (+0.79%)
Nemaura Medical Inc. (NMRD)
Nemaura Medical Inc.
57 West 57th Street
Manhattan
New York, NY 10019
United States
646 416 8000
https://nemauramedical.com
Sector(es): Healthcare
Industria: Medical Devices
Empleados a tiempo completo: 36
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Dewan Fazlul Hoque Chowdhury Ph.D. | Chairman, Interim CFO, CEO, President and Principal Financial & Accounting Officer | 338.58k | N/D | 1973 |
| Dr. Arash Ghadar | Chief Operating Officer | N/D | N/D | 1977 |
| Mr. Jay L. Warner | Head of U.S. Commercial Operations | N/D | N/D | N/D |
| Mr. Thomas Bendix Mortensen | Head of E.U. Commercial Operations & Marketing | N/D | N/D | N/D |
| Ms. Samantha Sanders | Global Head of Digital Programs | N/D | N/D | N/D |
Descripción
Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.
Gestión corporativa
La calificación ISS Governance QuickScore de Nemaura Medical Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
